Aspirin and the risk of prostate cancer

Cristina Bosetti, Renato Talamini, Eva Negri, Silvia Franceschi, Maurizio Montella, Carlo La Vecchia

Research output: Contribution to journalArticlepeer-review


Epidemiological studies have suggested that aspirin may have a protective effect against prostate cancer, but the evidence is still limited and inconsistent The role of aspirin in prostate cancer risk was analysed in a multicentric case-control study conducted in Italy between 1991 and 2002, including 1261 incident cases of carcinoma of the prostate and 1131 hospital controls. A total of 115 (9.1%) cases versus 90 (8.0%) controls reported regular aspirin use. The multivariate odds ratio (OR) for regular aspirin users was 1.10 (95% confidence interval (95% Cl) 0.81-1.50). No relation was found with duration of use (OR=1.03 for <5 years, and 1.17 for ≥ 5 years) and time since first use (OR=1.03 for <10 years, and 1.35 for ≥ 10 years). These findings do not support a protective role of regular aspirin use on prostate cancer risk.

Original languageEnglish
Pages (from-to)43-45
Number of pages3
JournalEuropean Journal of Cancer Prevention
Issue number1
Publication statusPublished - Feb 2006


  • Aspirin
  • Case-control study
  • Prostate cancer
  • Risk factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Aspirin and the risk of prostate cancer'. Together they form a unique fingerprint.

Cite this